0709 203000 - Nairobi 0709 983000 - Kilifi
0709 203000 - NRB 0709 983000 - Kilifi
0709 203000 - NRB | 0709 983000 - Kilifi

Management

Bio

Mainga Hamaluba MBChB MD FRCPCH Head of Clinical Research. Mainga is a paediatrician and works on clinical trials of vaccines, human infections studies and neonatal care. She is Principal Investigator (PI) and lead of the R21 clinical development programme in Kenya which includes the first evaluation of R21 in Africa (Phase 1b and the ongoing phase 3 trials). This is complemented by a vaccine efficacy Human Infection Study where she is Co-PI. Furthermore, she is PI for a phase 1/2 (First-In-Human and phase 2 trial of the leading tetravalent candidate shigella vaccine); sponsored by LimmaTech Biologics Ag. She also has clinical oversight of the broad portfolio of KWTRP team Human Infection Study platforms for malaria and shigella. These complementary programs continue to accelerate the clinical development of malaria and shigella vaccines.

See more

Current Work

Her current research focus is part of the Calestous Juma Fellowship funded by the Bill and Melinda Gates Foundation. This fellowship supports setting up a platform trial of neonatal interventions in coastal Kenya with a plan to expand this regionally to reduce neonatal mortality. She is currently supervising 1 PhD student working on snakebite research and has co-supervised MSc and PGDip studentships. She is currently PI or Co-PI of 9 clinical trials.

See more

Recent publications

Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria.
Musasia, F. K., Nkumama, I. N., Frank, R., Kipkemboi, V., Schneider, M., Mwai, K., Odera, D. O., Rosenkranz, M., Furle, K., Kimani, D., Tuju, J., Njuguna, P., Hamaluba, M., Kapulu, M. C., Wardemann, H., CHMI-SIKA Study Team., Osier, F. H. A.
Nat Commun, (2022). 13:4098

Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?.
van der Pluijm, R. W., Peto, T. J., Hamaluba, M., Callery, J. J., Tripura, R., White, N. J., Dondorp, A. M.
Lancet Infect Dis, (2022). 22:765-766

Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response.
Kapulu, M. C., Kimani, D., Njuguna, P., Hamaluba, M., Otieno, E., Kimathi, R., Tuju, J., Sim, B. K. L., CHMI-SIKA Study Team
BMC Infect Dis, (2022). 22:86

TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults).
Abouyannis, M., FitzGerald, R., Ngama, M., Mwangudzah, H., Nyambura, Y. K., Ngome, S., Riako, D., Babu, L., Lewa, F., Else, L., Dily Penchala, S., Orindi, B., Mumba, N., Kalama, B., Ndungu, F. M., Adetifa, I., Khoo, S., Lalloo, D. G., Casewell, N. R., Hamaluba, M.
Wellcome Open Res, (2022). 7:90

Undertaking Community Engagement for a Controlled Human Malaria Infection Study in Kenya: Approaches and Lessons Learnt.
Mumba, N., Njuguna, P., Chi, P., Marsh, V., Awuor, E., Hamaluba, M., Mauncho, C., Mwalukore, S., Masha, J., Mwangoma, M., Kalama, B., Alphan, H., Wambua, J., Bejon, P., Kamuya, D., Kapulu, M. C.
Front Public Health, (2022). 10:793913